EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The role of the efflux transporter, P‐glycoprotein, at the blood–brain barrier in drug discovery

Benoit Cox iD, Johan Nicolaï, Beth Williamson iD

Biopharmaceutics & Drug Disposition · 2023-02 · 44 (1) · 113-126

DOI: 10.1002/bdd.2331 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biopharmaceutics & Drug Disposition, online erschienen am 17.10.2022. Verfasst von Benoit Cox und 2 weiteren Autor:innen. Beteiligte Einrichtung: DMPK, Development Sciences, UCB Biopharma, Braine-l'Alleud, Belgium. Hauptthemen laut MEDLINE: Blood-Brain Barrier, ATP Binding Cassette Transporter, Subfamily B, Member 1. Die Arbeit wurde bisher 68-mal zitiert (Crossref) und nennt 120 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The blood–brain barrier (BBB) expresses a high abundance of transporters, particularly P‐glycoprotein (P‐gp), that regulate endogenous and exogenous molecule uptake and removal of waste. This review discusses key drug metabolism and pharmacokinetic considerations for the efflux transporter P‐gp at the BBB in drug discovery and development. We highlight the differences in P‐gp expression and protein levels across species but the limited observations of species‐specific substrates. Given the impact of age and disease on BBB biology, we summarise the modulation of P‐gp for several neurological disorders and ageing and exemplify several disease‐specific hurdles or opportunities for drug exposure in the brain. Furthermore, the review includes observations of CNS‐related drug‐drug interactions due to the inhibition or induction of P‐gp at the BBB in animal studies and humans and the need for continued evaluation especially for compounds with a narrow therapeutic window. This review focusses primarily on small molecules but also considers the impact of new chemical entities, particularly beyond Ro5 molecules and their potential to be recognised as P‐gp substrates as well as advanced drug delivery systems which offer an alternative approach to achieve and sustain central nervous system exposure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood-Brain BarrierATP Binding Cassette Transporter, Subfamily B, Member 1AnimalsHumansBrainATP Binding Cassette Transporter, Subfamily BMembrane Transport ProteinsDrug Discovery

Stichwörter der Autor:innen

BBBCNSP-glycoproteindrug discovery

Substanzen

ATP Binding Cassette Transporter, Subfamily B, Member 1ATP Binding Cassette Transporter, Subfamily BMembrane Transport Proteins

Autor:innen und Institutionen

  • DMPK, Development Sciences, UCB Biopharma, Braine-l'Alleud, Belgium.
  • DMPK, Janssen Pharmaceutical Companies of Johnson & Johnson, Janssen Research & Development, Beerse, Belgium.
  • DMPK, Development Sciences, UCB Biopharma, Slough, UK.

ORCID-Profile: Benoit Cox, Beth Williamson

Zitieren

APA

Cox, B., Nicolaï, J., & Williamson, B. (2023). The role of the efflux transporter, P‐glycoprotein, at the blood–brain barrier in drug discovery. Biopharmaceutics & Drug Disposition, 44(1), 113-126. https://doi.org/10.1002/bdd.2331

Vancouver

Cox B, Nicolaï J, Williamson B. The role of the efflux transporter, P‐glycoprotein, at the blood–brain barrier in drug discovery. Biopharmaceutics & Drug Disposition. 2023;44(1):113-126. doi:10.1002/bdd.2331

BibTeX
@article{Cox2023,
  author = {Cox, Benoit and Nicolaï, Johan and Williamson, Beth},
  title = {The role of the efflux transporter, P‐glycoprotein, at the blood–brain barrier in drug discovery},
  journal = {Biopharmaceutics & Drug Disposition},
  year = {2023},
  volume = {44},
  number = {1},
  pages = {113--126},
  doi = {10.1002/bdd.2331}
}
Kostenlos starten →